ARCHIVES

Study Tests PARP Inhibitor ABT-888 For Several Cancers

This article is from The Cancer Letter archive.

Vol. 32 No. 9 | September 25, 2009

Download PDF Visit The Full Archive

Related Articles

Votrient Trial Meets PFS Endpoint In Epithelial Ovarian Cancer

June 28, 2013

NCI Offers 200 Cell Lines to Scientist

May 6, 1983

Drug Marketing; Zeneca sues Eli Lilly, Claiming Misleading Promotion of Evista

March 12, 1999

Nexavar Improves PFS In Phase III Trial

January 25, 2013

In Brief: Fredrickson Will Stay As NIH Director; NCI Group to Study Rhoads’ Clinical Center Idea

February 11, 1977

In Brief: Breakthrough Prize Awarded to 11 Scientists

March 8, 2013